e-learning
resources
Munich 2014
Monday, 08.09.2014
Biology and pathology of thoracic tumours
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Decreased apoptosis rate of alveolar lymphocytes (AL) in patients with stage I-IIA non-small cell lung cancer (NSCLC)
A. Gizycka, J. Chorostowska-Wynimko, C. Rybacki, A. Dyczek, T. Wandtke, P. Kopinski (Warsaw, Bydgoszcz, Cracow, Poland)
Source:
International Congress 2014 – Biology and pathology of thoracic tumours
Session:
Biology and pathology of thoracic tumours
Session type:
Thematic Poster Session
Number:
2704
Disease area:
Thoracic oncology
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
A. Gizycka, J. Chorostowska-Wynimko, C. Rybacki, A. Dyczek, T. Wandtke, P. Kopinski (Warsaw, Bydgoszcz, Cracow, Poland). Decreased apoptosis rate of alveolar lymphocytes (AL) in patients with stage I-IIA non-small cell lung cancer (NSCLC). Eur Respir J 2014; 44: Suppl. 58, 2704
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Panel discussion: ANCA associated vasculitis and lung disease
Panel discussion on genetics in pulmonary fibrosis
The new challenge of CTD-ILD: from basic science to clinical setting
Related content which might interest you:
Increased expression of WSX1 on alveolar lymphocytes (AL) in patients with early stage non-small cell lung cancer (NSCLC). Preliminary report
Source: International Congress 2014 – Biology and pathology of thoracic tumours
Year: 2014
Alvolar lymphocytes (AL) in patients with non-small cell lung cancer (NSCLC). Data from tumor-affected lobe
Source: International Congress 2015 – Connective tissue disorders
Year: 2015
Evaluation of IL-33 level in serum and bronchoalveolar lavage fluid of patients with non-small cell lung cancer (NSCLC)
Source: International Congress 2014 – Biology and pathology of thoracic tumours
Year: 2014
Cytotoxic phenotype of alveolar lymphocytes (AL) in bronchoalveolar lavage fluid (BALF) from non-small cell lung cancer (NSCLC) patients
Source: International Congress 2014 – New mechanisms in the pathogenesis of asthma and other lung diseases
Year: 2014
Evaluation of IL-10 level in serum and bronchoalveolar lavage fluid of patients with non-small cell lung cancer (NSCLC)
Source: Annual Congress 2013 –Prognostic factors and subtyping of lung cancer
Year: 2013
Inflammasome pathway activation in patients with non-small cell lung cancer (NSCLC): A bronchoalveolar lavage fluid study
Source: Annual Congress 2013 –Pathogenesis and risk of lung cancer
Year: 2013
Changes in lymphocyte subgroups of non-small cell lung cancer patients during chemotherapy
Source: International Congress 2015 – Cell biology of lung cancer and new biomarkers
Year: 2015
Comparing performance and cost of EBUS-TBNA versus other methods for diagnosis and staging of non-small cell lung cancer (NSCLC)
Source: International Congress 2014 – Improving diagnosis of thoracic tumours
Year: 2014
Molecular analysis of peripheral non-squamous non-small cell lung cancer sampled by radial EBUS
Source: International Congress 2016 – Endosonography: EBUS/EUS (B)
Year: 2016
Functional impairment of NK cells in non-small-cell lung cancer
Source: International Congress 2014 – Biology and pathology of thoracic tumours
Year: 2014
CD33
+
CD14
-
CD11b
+
CD66b
+
CD15
+
VEGFR-1
hi
myeloid derived suppressor cells and their clinical relevance in non-small cell lung cancer
Source: International Congress 2014 – Biology and pathology of thoracic tumours
Year: 2014
Procalcitonin serum levels in patients with stage IV non-small cell lung cancer in first line of chemotherapy
Source: International Congress 2016 – Clinical aspects of lung cancer
Year: 2016
Molecular signatures of non-small cell lung cancer (NSCLC) obtained from gene expression profiling of the benign bronchial mucosa of smokers with and without NSCLC
Source: Annual Congress 2013 –Biology and molecular pathology of lung cancer
Year: 2013
Prognostic impact of secondary malignancies in non-small cell lung cancer (NSCLC)
Source: International Congress 2015 – Lung cancer: prognostic factors and features of oncogene-driven tumours
Year: 2015
Response to chemotherapy as a predictor of survival in advanced non-small cell lung cancer (NSCLC)
Source: International Congress 2015 – Diagnosis and therapy of lung cancer
Year: 2015
EGFRmutations are associated with higher brain metastasis radio-sensitivity than KRAS mutations or wild type EGFR in non-small cell lung cancer patients (NSCLC)
Source: International Congress 2014 – Therapy of thoracic tumours: clinical trials and case series
Year: 2014
Screening for intracerebral metastasis in radically treated non-small cell lung cancer patients
Source: International Congress 2016 – Lung cancer: therapeutic modalities, re-staging, and follow-up
Year: 2016
Surgical treatmment non-small cell lung cancer in the elderly patients
Source: International Congress 2015 – Diagnosis and therapy of lung cancer
Year: 2015
Neutrophil to lymphocyte ratio (NLR) as a predictor of poor prognosis in advanced non-small cell lung cancer
Source: International Congress 2016 – Lung cancer and immune cells: friends or foes?
Year: 2016
Survival of non small cell lung carcinoma patients with malignant pleural effusions
Source: International Congress 2014 – Therapy of thoracic tumours: clinical trials and case series
Year: 2014
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept